Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 30, 2025 → Jun 24, 2026
Coverage: 247 bars · Jun 30, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Halo Collective Inc. (HCANF) is a Healthcare stock with a market cap of $150.00M and listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 30, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of -32.2%, EPS growth of +97.5%, a dividend yield of 0.0%. What stands out right now is revenue -32.2%, EPS +97.5%, free cash flow +63.9% with operating margin -142.2% and ROIC -45.9%. Valuation sits in the middle of the pack at price/sales 4.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HCANF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
HCANF is 18.68 pts behind over the shared 1Y window.
HCANF had 9.13 pts shallower max drawdown than SPY.
HCANF beat SPY in 0 of 2 calendar years shown and trailed in 2.
HCANF
+0.00%
Normalized return
SPY
+18.68%
S&P 500
Excess Return
-18.68 pts
Relative to SPY
HCANF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for HCANF and SPY.
| Year | HCANF | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | 0.00% | +6.71% | -6.71 pts | SPY |
| 2025 | 0.00% | +11.19% | -11.19 pts | SPY |
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$10.9M
-61.3% YoY
FY Net Income
-$13.7M
+50.3% YoY
Free Cash Flow
-$15.7M
+6.2% YoY
Revenue Growth
-32.2%
EPS Growth
+97.5%
Gross Margin
21.1%
Net Margin
-345.2%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 25M | 36M | 22M | 28M | 11M |
| Gross Profit | 5M | 4M | 4M | 3M | -268K |
| Operating Income | -35M | -42M | -21M | -22M | -10M |
| EBITDA | -74M | -38M | -38M | -25M | -12M |
| Net Income | -84M | -95M | -41M | -28M | -14M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 944K | 2M | 3M | 4M | 723K |
| Total Assets | 57M | 105M | 88M | 42M | 19M |
| Total Liabilities | 27M | 38M | 28M | 18M | 5M |
| Shareholder Equity | 33M | 69M | 60M | 24M | 15M |
| Total Debt | 18M | 25M | 19M | 10M | 505K |
| Net Debt | 17M | 23M | 16M | 6M | -218K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
+16.2% YoY
Capital Expenditures
3M
-66.3% YoY
Free Cash Flow
16M
+6.2% YoY
Key ratios
Gross Margin
21.1%
Operating Margin
-142.2%
Net Margin
-345.2%
ROE
-147.4%
Debt / Equity
0.36x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.